O	0	5	Seven
O	5	6	-
O	6	10	year
O	11	17	follow
O	17	18	-
O	18	20	up
O	21	31	assessment
O	32	34	of
O	35	42	cardiac
O	43	51	function
O	52	54	in
O	55	60	NSABP
O	61	62	B
O	62	63	-
O	63	65	31
O	65	66	,
O	67	68	a
O	69	79	randomized
O	80	85	trial
O	86	95	comparing
B-intervention	96	107	doxorubicin
I-intervention	108	111	and
I-intervention	112	128	cyclophosphamide
I-intervention	129	137	followed
I-intervention	138	140	by
I-intervention	141	151	paclitaxel
I-intervention	152	153	(
I-intervention	153	156	ACP
I-intervention	156	157	)
I-intervention	158	162	with
I-intervention	163	166	ACP
I-intervention	167	171	plus
I-intervention	172	183	trastuzumab
O	184	186	as
O	187	195	adjuvant
O	196	203	therapy
O	204	207	for
B-eligibility	208	216	patients
I-eligibility	217	221	with
I-eligibility	222	226	node
I-eligibility	226	227	-
I-eligibility	227	235	positive
I-eligibility	235	236	,
I-eligibility	237	242	human
I-eligibility	243	252	epidermal
I-eligibility	253	259	growth
I-eligibility	260	266	factor
I-eligibility	267	275	receptor
I-eligibility	276	277	2
I-eligibility	277	278	-
I-eligibility	278	286	positive
I-eligibility	287	293	breast
I-eligibility	294	300	cancer
O	300	301	.

O	302	309	Cardiac
O	310	321	dysfunction
O	322	323	(
O	323	325	CD
O	325	326	)
O	327	329	is
O	330	331	a
O	332	342	recognized
O	343	347	risk
O	348	358	associated
O	359	363	with
O	364	367	the
O	368	376	addition
O	377	379	of
O	380	391	trastuzumab
O	392	394	to
O	395	403	adjuvant
O	404	416	chemotherapy
O	417	420	for
O	421	426	human
O	427	436	epidermal
O	437	443	growth
O	444	450	factor
O	451	459	receptor
O	460	461	2
O	461	462	-
O	462	470	positive
O	471	477	breast
O	478	484	cancer
O	484	485	,
O	486	496	especially
O	497	501	when
O	502	505	the
O	506	515	treatment
O	516	523	regimen
O	524	532	includes
O	533	547	anthracyclines
O	547	548	.

O	549	554	Given
O	555	558	the
O	559	571	demonstrated
O	572	580	efficacy
O	581	583	of
O	584	595	trastuzumab
O	595	596	,
O	597	604	ongoing
O	605	615	assessment
O	616	618	of
O	619	626	cardiac
O	627	633	safety
O	634	637	and
O	638	652	identification
O	653	655	of
O	656	660	risk
O	661	668	factors
O	669	672	for
O	673	675	CD
O	676	679	are
O	680	689	important
O	690	693	for
O	694	701	optimal
O	702	709	patient
O	710	714	care
O	714	715	.

O	716	718	In
O	719	727	National
O	728	736	Surgical
O	737	745	Adjuvant
O	746	752	Breast
O	753	756	and
O	757	762	Bowel
O	763	770	Project
O	771	772	B
O	772	773	-
O	773	775	31
O	775	776	,
O	777	778	a
O	779	784	phase
O	785	788	III
O	789	797	adjuvant
O	798	803	trial
O	803	804	,
B-total-participants	805	806	1
I-total-participants	806	807	,
I-total-participants	807	810	830
O	811	819	patients
O	820	823	who
O	824	827	met
O	828	839	eligibility
O	840	848	criteria
O	849	852	for
O	853	863	initiation
O	864	866	of
O	867	878	trastuzumab
O	879	883	were
O	884	893	evaluated
O	894	897	for
O	898	900	CD
O	900	901	.

O	902	910	Recovery
O	911	915	from
O	916	918	CD
O	919	922	was
O	923	927	also
O	928	936	assessed
O	936	937	.

O	938	939	A
O	940	951	statistical
O	952	957	model
O	958	961	was
O	962	971	developed
O	972	974	to
O	975	983	estimate
O	984	987	the
O	988	992	risk
O	993	995	of
O	996	1002	severe
O	1003	1013	congestive
O	1014	1019	heart
O	1020	1027	failure
O	1028	1029	(
O	1029	1032	CHF
O	1032	1033	)
O	1033	1034	.

O	1035	1043	Baseline
O	1044	1051	patient
O	1052	1067	characteristics
O	1068	1078	associated
O	1079	1083	with
O	1084	1097	anthracycline
O	1097	1098	-
O	1098	1105	related
O	1106	1113	decline
O	1114	1116	in
O	1117	1124	cardiac
O	1125	1133	function
O	1134	1138	were
O	1139	1143	also
O	1144	1154	identified
O	1154	1155	.

O	1156	1158	At
O	1159	1160	7
O	1160	1161	-
O	1161	1165	year
O	1166	1172	follow
O	1172	1173	-
O	1173	1175	up
O	1175	1176	,
B-iv-bin-abs	1177	1179	37
O	1180	1181	(
B-iv-bin-percent	1181	1182	4
I-iv-bin-percent	1182	1183	.
I-iv-bin-percent	1183	1184	0
I-iv-bin-percent	1184	1185	%
O	1185	1186	)
O	1187	1189	of
B-intervention-participants	1190	1193	944
O	1194	1202	patients
O	1203	1206	who
O	1207	1215	received
O	1216	1227	trastuzumab
O	1228	1239	experienced
O	1240	1241	a
B-outcome	1242	1249	cardiac
I-outcome	1250	1255	event
I-outcome	1256	1257	(
I-outcome	1257	1259	CE
I-outcome	1259	1260	)
O	1261	1267	versus
B-cv-bin-abs	1268	1270	10
O	1271	1272	(
B-cv-bin-percent	1272	1273	1
I-cv-bin-percent	1273	1274	.
I-cv-bin-percent	1274	1275	3
I-cv-bin-percent	1275	1276	%
O	1276	1277	)
O	1278	1280	of
B-control-participants	1281	1284	743
O	1285	1293	patients
O	1294	1296	in
O	1297	1300	the
B-control	1301	1308	control
O	1309	1312	arm
O	1312	1313	.

B-iv-bin-abs	1314	1317	One
B-outcome	1318	1325	cardiac
I-outcome	1325	1326	-
I-outcome	1326	1333	related
I-outcome	1334	1339	death
O	1340	1343	has
O	1344	1352	occurred
O	1353	1355	in
O	1356	1360	each
O	1361	1364	arm
O	1365	1367	of
O	1368	1371	the
O	1372	1380	protocol
O	1380	1381	.

O	1382	1383	A
O	1384	1391	Cardiac
O	1392	1396	Risk
O	1397	1402	Score
O	1402	1403	,
O	1404	1414	calculated
O	1415	1420	using
O	1421	1428	patient
O	1429	1432	age
O	1433	1436	and
O	1437	1445	baseline
O	1446	1450	left
O	1451	1462	ventricular
O	1463	1471	ejection
O	1472	1480	fraction
O	1481	1482	(
O	1482	1486	LVEF
O	1486	1487	)
O	1488	1490	by
O	1491	1499	multiple
O	1499	1500	-
O	1500	1505	gated
O	1506	1517	acquisition
O	1518	1522	scan
O	1522	1523	,
O	1524	1537	statistically
O	1538	1548	correlates
O	1549	1553	with
O	1554	1557	the
O	1558	1562	risk
O	1563	1565	of
O	1566	1567	a
O	1568	1570	CE
O	1570	1571	.

O	1572	1577	After
O	1578	1586	stopping
O	1587	1598	trastuzumab
O	1598	1599	,
O	1600	1603	the
O	1604	1612	majority
O	1613	1615	of
O	1616	1624	patients
O	1625	1628	who
O	1629	1640	experienced
O	1641	1643	CD
O	1644	1653	recovered
O	1654	1658	LVEF
O	1659	1661	in
O	1662	1665	the
O	1666	1672	normal
O	1673	1678	range
O	1678	1679	,
O	1680	1688	although
O	1689	1693	some
O	1694	1701	decline
O	1702	1706	from
O	1707	1715	baseline
O	1716	1721	often
O	1722	1730	persists
O	1730	1731	.

O	1732	1736	Only
O	1737	1740	two
B-outcome	1741	1744	CEs
O	1745	1753	occurred
O	1754	1758	more
O	1759	1763	than
O	1764	1765	2
O	1766	1771	years
O	1772	1777	after
O	1778	1788	initiation
O	1789	1791	of
O	1792	1803	trastuzumab
O	1803	1804	.

O	1805	1808	The
O	1809	1813	late
O	1814	1825	development
O	1826	1828	of
O	1829	1832	CHF
O	1833	1838	after
O	1839	1842	the
O	1843	1851	addition
O	1852	1854	of
O	1855	1866	trastuzumab
O	1867	1869	to
O	1870	1880	paclitaxel
O	1881	1886	after
O	1887	1898	doxorubicin
O	1898	1899	/
O	1900	1916	cyclophosphamide
O	1917	1929	chemotherapy
O	1930	1932	is
O	1933	1941	uncommon
O	1941	1942	.

O	1943	1946	The
O	1947	1951	risk
O	1952	1958	versus
O	1959	1966	benefit
O	1967	1969	of
O	1970	1981	trastuzumab
O	1982	1984	as
O	1985	1990	given
O	1991	1993	in
O	1994	1998	this
O	1999	2006	regimen
O	2007	2014	remains
O	2015	2023	strongly
O	2024	2026	in
O	2027	2032	favor
O	2033	2035	of
O	2036	2047	trastuzumab
O	2047	2048	.
